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Available online 4 May 2016Objective: To assess the effect of training general practitioners (GPs) in the optimization of drug treatment for
newly detected heart failure (HF).
Design: Cluster randomized trial comparing the training programme to care as usual.
Participants: Community-dwelling older persons with a new HF diagnosis after diagnostic work-up.
Methods: Thirty GPs were randomized to care as usual or the training. Sixteen GPs of the latter group received a
half-day training on optimizing HF medication in HF patients with a reduced (HFrEF), or with a preserved ejec-
tion fraction (HFpEF). At baseline and after sixmonths of follow-up, the 46 HF patients in the intervention group
and the 46 cases in the care as usual group were assessed on medication use, functionality, health status, and
health care visits.
Results: After 6 months, uptake of HFmedication and health status were similar in the two groups. Interestingly,
patients in the intervention group had a longer walking distance with the six-minute walk test than those in the
care as usual group (mean difference in all-type HF 28.0 (95% CI 2.9 to 53.1) meters; HFpEF patients 28.2 (95% CI
8.8 to 47.5) meters and HFrEF patients 55.9 (95% CI−16.3 to 128.1) meters). They also had more HF-related GP
visits (RR 1.8, 95% CI 1.3 to 2.5) and fewer visits to the cardiologist (RR 0.6, 95% CI 0.3 to 1.1).
Conclusions: Training GPs in optimization of drug treatment of newly detected HFrEF and HFpEF did not clearly
increase HF medication, but resulted in improvement in walking distance.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Heart failure (HF) is a progressive chronic syndrome causing symp-
toms such as shortness of breath, fatigue and ﬂuid retention. It is a com-
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land Ltd. This is an open access articllarge, with a prevalence rising from 0.8% in the group of 55–64 year
olds to 20% among the age group of 85 years and older [1].
Heart failurewith reduced ejection fraction (HFrEF) andheart failure
with preserved ejection fraction (HFpEF) are the major phenotypes
within the HF spectrum. Both are disabling conditions with high mor-
bidity and mortality, and a substantial loss in functional capacity and
health status [2]. The impact on health status is in general larger than
for other chronic diseases such as osteo-arthritis, chronic obstructive
pulmonary disease (COPD), and depression [3]. Reduced physical func-
tioning seems to be a main driving force behind this.
Management of HF is complex. The European Society of Cardiology
(ESC) provides guidance on patient counselling, including advices on
lifestyle, how to optimize HFmedication,monitor the individual clinical
course of the disease and patient speciﬁc comorbidities, and when to
consider devices [4]. For HFrEF the recommendations on initiation of
drug treatment are clear: loop diuretics in case of volume overload,
and mortality-reducing treatment with beta-blockers and angiotensin-
converting enzyme inhibitors (ACE-inhibitors) (or when intolerated
angiotensin receptor blockers (ARBs)), followed by mineralocorticoide under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ARBs and beta-blockers need to be up-titrated, ‘starting low, going
slow’, targeting for recommended doses. For HFpEF the guidance on
drug treatment is less clear, because clear evidence-based mortality-
reducing treatment is lacking. Diuretics are useful for symptom relief
in case of sodium and water retention in HFpEF patients, while blood
pressure and comorbidities should be adequately managed [4].
The majority of patients with HF is primarily diagnosed and treated
by their general practitioner (GP) [5], but treatment in the primary care
setting seems suboptimal [6–8]. Physician-related barriers to guideline
adherence include deﬁcits in knowledge, skills, and lack of conﬁdence
to up-titratemedication [9–11]. Hence, education seems indicated to in-
crease GPs' knowledge and competence on initiating HF drug therapy,
and this could improve their patients' health status.
The aim of the present study was to evaluate whether a single half-
day training of GPs in the practical application of a scheme to optimize
HF drug treatment in newly detected patients with HFrEF and HFpEF
results in improvements in uptake of HF medication, functional capaci-
ty, health status, and inﬂuences the number of health care visits.
2. Methods
2.1. Trial design
This cluster randomized trial was the second part of a combined
diagnostic-therapeutic study conducted between December 2010 and
December 2012 with the aim to improve both the diagnosis and treat-
ment of HF in primary care. The diagnostic part included selective screen-
ing for HF of older persons who visited their GP with shortness of breath
within the last 12 months. Among these patients, those with newly de-
tected HF were eligible for this cluster randomized therapeutic study.
Random allocation to one of the treatment groups was executed at
the level of the GP. As a result, patients with HF of one GP (a cluster)
were all managed according to the same arm, hereby reducing the risk
of contamination between patient groups. After a six month follow-up
period outcomes were compared between groups, taking clustering
into account. The study protocol was published previously [12].
2.2. Participants
General practices in the Zeist region in the center of the Netherlands,
were invited to participate in this study. A total of thirty practices were
recruited.
Persons aged 65 years or over who in the previous 12 months pre-
sented themselves to the GP with shortness of breath on exertion
were selected from the electronic medical ﬁles of the participating GPs
by a single physician (EvR). The selection was irrespective of whether
persons were suspected of HF by the GP or not, or any prior non-HF di-
agnosis; thus, patients knownwith a pulmonary diseasewere also eligi-
ble. Those already known with an established diagnosis of HF,
conﬁrmed with echocardiography by the cardiologist, were excluded,
as were patients with a life expectancy shorter than six months, and
those unable to give informed consent. Informed consent was obtained
from all participants and the study was performed according to the
principles of the current version of the declaration of Helsinki.
Participants underwent a standardised diagnostic work-up conduct-
ed at the outpatient clinic of the Julius Center in Utrecht, or were visited
at home if they were unable to travel to the study center. Diagnostic
investigations included history taking, physical examination, electrocar-
diography (ECG), and a blood test for N-terminal pro B-type natriuretic
peptide (NTproBNP) levels. Only participants with an abnormal ECG or
NTproBNP levels above 125 pg/ml (15 pmol/l) underwent additional
echocardiography, in accordance with the ESC HF guidelines [4], in the
outpatient clinic of the Diakonessenhuis Hospital Zeist.
An expert panel consisting of two cardiologists (AL andML) and aGP
with special expertise in HF (FR) established or excluded HF followingthe latest criteria on HF of the ESC [4]. HF was further classiﬁed in
HFrEF (deﬁned as an ejection fraction ≤45%), HFpEF (deﬁned as an ejec-
tion fraction N45% in combination with structural or functional abnor-
malities compatible with diastolic dysfunction) and ‘isolated’ right-
sided HF. The study population of the trial consisted of the participants
with newly detected HF according to the expert panel, except for those
having a potentially treatable cause of their HF, who were directly
referred to a cardiologist.
2.3. Interventions
The intervention consisted of a single half-day educational session.
The GPs in this arm received training in the optimization of HF drug
treatment for both HFrEF and HFpEF. They received detailed instruc-
tions on how and when to initiate diuretics and initiate and up-titrate
ACE-inhibitors (or ARBs in case of intolerance to ACE-inhibitors), beta-
blockers and possibly MRAs, in patients with HFrEF. For those with
HFpEF, individualised titration of diuretic therapy was explained, and
also the importance of optimal blood pressure control, and in those
with atrial ﬁbrillation, heart rate control [4]. See Fig. 1 for a simpliﬁed
version of the initiation- and up-titration scheme, and the Additional
ﬁle for the full content of the scheme. The protocol was designed to
guide the GPs through the optimization steps to be fulﬁlled within
three months after the new diagnosis of HF.
During the training session, special attention was given to potential
barriers in HFdrug treatment, such as fear of adverse effects andworries
about ACE-inhibitors and beta-blockers in patients with comorbidities
or polypharmacy [10].
The GPs randomly allocated to the care as usual group managed
their newly detected cases of HF as they were used to, and did not re-
ceive the training. Both groupshad access to theDutchGPs'HF guideline
(‘NHG-standaard Hartfalen 2010’) [13], a Dutch equivalent of the ESC
Guideline on HF [4]. Referral to a cardiologist was possible at any
stage in this pragmatic trial.
2.4. Outcomes
2.4.1. HF medication uptake
During the diagnostic work-up at baseline, patients were asked
about their current drug use. In a preparatory letter, they were asked
to bring their medication containers or a list of prescribed medication.
Six months after the diagnosis of HF, the electronic medical ﬁles of
GPs were scrutinized for medication changes. Changes within groups
and differences between the two groups regarding use of diuretics,
ACE-inhibitors or ARBs and beta-blockers after six months of follow-
up were assessed.
2.4.2. Functional capacity
Especially for older persons exercise tolerance is ofmajor clinical im-
portance. Of the several modalities available, the six-minute walk test
(6MWT)was used for the objective evaluation of functional capacity be-
cause the exercise level is consistent with daily physical activities [14].
The 6MWT is considered a valid, well-tolerated, and inexpensive test
for functional capacity, that measures the distance that a patient can
walk on a ﬂat, hard surface during 6 min [15]. The test was executed
according to the guidelines of the American Thoracic Society, at baseline
(at the time of diagnosis) and after six months follow-up [14]. In gener-
al, an increase of 50 m in walking distance is considered a ‘substantial
improvement’, and an increase of 20 m a ‘small meaningful change’
[16,17].
2.4.3. Health status
The EuroQol-5 Dimensions (EQ-5D) and the Short Form-36 (SF-36)
were chosen as instruments to measure general health status. Both
questionnaires have been extensively validated and are widely used
[18–21].
Fig. 1. Simpliﬁed version of the treatment scheme for heart failure.
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bility, self-care, usual activities, pain/discomfort, and anxiety/depression.
A single index score can be produced using data from the ﬁve dimen-
sions; a score of 1.0 represents perfect health and 0 represents death.
The SF-36 provides an eight-dimension health proﬁle with the fol-
lowing subscales; physical functioning, role limitation due to physical
problems, bodily pain, general health, vitality, social functioning, role
limitation due to emotional problems, andmental health, and two sum-
mary scores for the physical and mental components (PCS and MCS).
Scores range from 0–100 with higher scores indicating a better health
status.
The Minnesota Living with Heart Failure (MLHF) questionnaire was
added as a condition-speciﬁc measurement of health status [22]. TheMLHF has 21 items and scores range from 0 to 105 with a low score
reﬂecting a better health status.
Minimal clinically important differences were estimated as follows;
0.074 for the EQ-5D [23], 10–15 points for PCS of the SF-36 [24], and 5
points for the MLHF questionnaire [25].
Baseline EQ-5D and SF-36 questionnaires were ﬁlled out by par-
ticipants during the diagnostic visit to our center. The baseline
MLHF questionnaire was disseminated through the general practi-
tioners at the time of diagnosis. This latter strategy resulted in a
large number of missings for the MLHF questionnaire, and therefore
we decided to change this strategy for the follow-up measurement.
The project manager (EvR) administered all three questionnaires
after six months follow-up.
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Information on the number of HF-related appointments with the GP
during six months of follow-up, and the number of (HF-related) refer-
rals to the cardiologist and HF-related hospitalizations during six and
twelve months following the new HF diagnosis were extracted from
the electronic medical ﬁles at the GP's ofﬁce, and differences in the
number of visits between groups were determined.
2.5. Sample size
We assumed that in a standard general practice with 2400 patients,
at least 50 patients aged 65 years or over experience shortness of breath
during a one-year period. The prevalence of newly detected HF in such
patients was expected to be around 14% [26]. With a participation rate
of 50%, a mean number of 3.5 patients with newly detected HF
(k) was expected per GP.
Because of the relevance of functional capacity for patients with HF,
the sample size calculation for this study was based on the difference in
mean distance walked during the 6MWT at baseline and after 6months
between the two groups.
We used the two-sample t-test power analysis to examine how
many HF patients were needed per group to demonstrate an effect on
the 6MWT.We anticipated an increase in walking distance in the inter-
vention group from 350m (standard deviation 85m) to 400m.With an
alpha of 0.05 and beta of 0.2, group sample sizes of two times 45
patients per arm would be sufﬁcient, that is, without taking clustering
into account.
We used an intra-cluster correlation coefﬁcient (ICC) of 0.05 to allow
for taking clustering into account [27]. The sample size from conven-
tional planning (n = 90) was inﬂated by a factor 1 + (k− 1) ∗ ICC =
1.13 [28], resulting in 104 participants; 52 per arm. Hence, we needed
to include 104/3.5 = 30 GP practices.
2.6. Randomization and blinding
Random allocation of the participating GPs to the intervention or
care as usual was undertaken by the project manager in a blinded
fashion.
Since it was not deemed feasible to keep the GPs in the care as usual
arm unaware of the existence of an intervention arm, blinding of the
participants was considered necessary to minimize bias in assessing
the outcome parameters. The researcher who performed the 6MWT
was blinded to the patient's allocation arm. The risk of observer bias
for the other endpoints wasminimized, because the health status ques-
tionnaires were ﬁlled out at home by the participants themselves, and
retrieving information on health care visits and HF medication from
the electronic medical ﬁles was not subject to interpretation.
2.7. Data analysis
Baseline characteristics of patients across the intervention and care
as usual group are presented as means or proportions. Data with a
skewed distribution are summarized as medians with an interquartile
range.
Due to the cluster design, patientswithin a practiceweremore likely
to be similar to one another than to patients in other practices regarding
characteristics such as age, ethnicity, and socioeconomic status, and
they were subject to the same physician's behaviour. Generalized esti-
mating equations (GEE) were used to account for clustering of patients
within practices. Robust variance estimates were used.
Comparison of the continuous outcomes (6MWT, health status) be-
tween the two study arms was done using a generalized linear model,
expressed as difference in means with 95% conﬁdence intervals (CIs).
Comparison of the count outcomes (health care visits) between the
two groupswas donewith a binary logistic model, and expressed as ad-
justed rate ratios (RRs) with 95% CIs. Analyses were also performedseparately for HFrEF and HFpEF. Patients with right-sided HF were cat-
egorized as HFpEF.
GEE analysis of continuous outcomes was performed in three steps;
1) without correction for baseline characteristics, 2) with adjustment
for baseline scores on the outcome (6MWT distance and health status),
and 3) as 2, but with the addition of baseline characteristics (age and
gender alone, and in combinationwith history of ischemic heart disease,
atrial ﬁbrillation and depression) as covariates in the models.
To prevent biased results due to incomplete data and selective loss
to follow-up, multiple imputation of missing values on health status
questionnaires and 6MWT was performed before GEE analyses [29,
30]. With regression methods, ﬁve imputation sets were created and
pooled estimates were obtained. For the three patients (3.3%) who
died during follow-up a score of zero was imputed as follow-up score
for EQ-5D and SF-36. Data were analysed using SPSS software (version
20.0 for Windows SPSS Inc. Chicago, IL, USA).
3. Results
Thirty GPs participated and 16were randomized to the intervention
group and 14 to the care as usual group. Of 1527 eligible patients, 585
gave written informed consent and were included in the diagnostic
part of the study. In 92 (15.7%, 95% CI 12.9 to 19.0) patients a new
diagnosis of HF was established; 17 (2.9%, 95% CI 1.8 to 4.7) with
HFrEF, 70 (12.0%, 95% CI 9.5 to 14.9) with HFpEF, and ﬁve (0.9%, 95%
CI 0.3 to 2.1) with isolated right-sided HF.
Five (0.9%) participants were referred directly to the cardiologist
after the diagnostic assessment; one with brady-arrhythmia, one with
an ascending aorta aneurysm, onewith grade IIImitral valve insufﬁcien-
cy, one with a large, old myocardial infarction, and ﬁnally one with
contradictory parameters on the echocardiogram.
All patients with newly detected HF proceeded to the cluster
randomized trial, in which 46 were treated by a GP in the intervention
group and 46 by a GP in the care as usual group (see Fig. 2 for the ﬂow-
chart of the study).
Themedian age of the trial participantswas 78.0 (interquartile range
74.0–82.0) years, and 52.2%were female (Table 1). Patients in the inter-
vention group were younger (median 76.0 vs. 79.5 years) and slightly
more often female (54.3% vs. 50.0%) than those in the care as usual
group. Ischaemic heart disease (26.1% vs. 39.1%), hypertension (65.2%
vs. 80.4%) and atrial ﬁbrillation (13.0% vs. 23.9%) were less common in
the intervention group. Baseline scores on the 6MWT and health status
questionnaires differed only slightly between the two groups.
3.1. HF medication uptake
At the endof the follow-up, 57% ofHFrEF patients in the intervention
group were prescribed a diuretic, 72% an ACE-inhibitor or ARB, 57% a
beta-blocker and none MRAs. These percentages were comparable to
HFrEF patients with care as usual: 60% were prescribed a diuretic, 70%
an ACE-inhibitor or ARB, 50% a beta-blocker and also none MRAs. The
majority in both groups already used these drugs at baseline, in only a
few cases new medication was started (Table 2). Also for HFpEF,
the percentage of patients in which medication was initiated or up-
titrated was similar in both groups.
3.2. Functional capacity
Of patients invited for the 6MWT, 74% participated at baseline and
71% at the follow-up. After correction for baseline scores of the 6MWT,
the patients in the intervention group walked on average 28.0 m (95%
CI 2.9 to 53.1) farther than the patients in the care as usual group at
follow-up (Table 3). The corresponding numbers for HFrEF and HFpEF
were 55.9 m (95% CI−16.3 to 128.1) and 28.2 m (95% CI 8.8 to 47.5),
respectively. The absolute mean distances walked by patients with
HFrEF were longer than those with HFpEF in both groups.
Fig. 2. Study ﬂowchart
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mean differences in the number of meters walked, but the difference
remained statistically signiﬁcant for patients with HFpEF (mean differ-
ence 21.8 m, 95% CI 0.2 to 43.4).3.3. Health status
All participants (100%) ﬁlled out the EQ-5D and SF-36 at baseline,
and nearly 90% completed these questionnaires at follow-up. For the
reasons outlined above, the MLHF questionnaire was completed by
only 20% at baseline, but by 80% at follow-up. Most scores on health
status remained the same or declined slightly in both the intervention
and care as usual group during follow-up and none of the scores dif-
fered between the groups (Table 3). HFrEF patients rated their quality
of life higher than HFpEF patients in both groups. The difference in
EQ-5D scores between HFrEF patients in the intervention and care as
usual group at follow-up exceeded the minimal clinically importantdifference, but was not statistically signiﬁcant (corrected mean differ-
ence 0.12, 95% CI−0.03 to 0.26).3.4. Health care visits
After six and twelve months of follow-up information on the num-
ber of health care visits and medication prescription was collected for
all but one patient, whose data were untraceable after changing of GP.
Patients in the intervention group had on average oneHF-related GP
visit extra compared to those in the care as usual group during six
months of follow-up (total number of visits 134 versus 80; mean num-
ber of visits 2.9 versus 1.7; RR 1.8; 95% CI 1.3 to 2.5). The intervention
group less often consulted a cardiologist for any reason (total number
of visits 22 versus 42; RR 0.6, 95% CI 0.3 to 1.1), and for HF (total number
of visits 6 versus 13; RR 0.5, 95% CI 0.1 to 1.5) during twelve months of
follow-up. The majority of referrals occurred in the ﬁrst six months
following the new HF diagnosis (Table 4).
Table 1
Baseline characteristics of 92 participants with newly detected heart failure divided by study arm.
Characteristics All
(n = 92)
Intervention
(n = 46)
Care as usual
(n = 46)
Age in years, median (IQR) 78.0
(74.0–82.0)
76.0
(73.0–81.0)
79.5
(74.8–83.0)
Female gender 48 (52.2) 25 (54.3) 23 (50.0)
Living situation
Independent, alone 34 (37.0) 18 (39.1) 16 (34.8)
Independent, with others 43 (46.7) 23 (50.0) 20 (43.5)
Dependent of care 15 (16.3) 5 (13.1) 10 (18.5)
Level of education
Primary 14 (15.2) 7 (15.2) 7 (15.2)
Secondary 52 (56.5) 25 (54.3) 27 (58.7)
Tertiary 26 (28.3) 14 (30.4) 12 (26.0)
MRC score ≥3a 52 (56.5) 27 (58.7) 25 (54.3)
BMI in kg/m2, mean (SD) 29.9 (4.6) 30.1 (5.5) 29.6 (3.5)
NT-proBNP in pg/mlb, median (IQR) 390 (203–754) 322 (195–623) 470 (242–964)
Abnormal ECGc 60 (65.9) 26 (57.8) 34 (73.9)
Comorbiditiesd
Ischemic heart diseasee 30 (32.6) 12 (26.1) 18 (39.1)
Atrial ﬁbrillation 17 (18.5) 6 (13.0) 11 (23.9)
Hypertension 67 (72.8) 30 (65.2) 37 (80.4)
Diabetes mellitus 21 (22.8) 11 (23.9) 10 (21.7)
Stroke or TIA 15 (16.3) 7 (15.2) 8 (17.4)
Asthma/COPD 44 (47.8) 22 (47.8) 22 (47.8)
Depressive symptoms 11 (12.0) 8 (17.4) 3 (6.5)
Medication
Loop diuretics 25 (27.2) 9 (19.6) 16 (34.8)
Thiazide diuretics 24 (26.1) 10 (21.7) 14 (30.4)
ACE-inhibitors/ARBs 59 (64.1) 27 (58.7) 32 (69.6)
β-Blockers 39 (42.4) 17 (37.0) 22 (47.8)
MRAs 4 (4.3) 1 (2.2) 3 (6.5)
Statins 37 (40.2) 14 (30.4) 23 (50.0)
Calcium channel-blockers 23 (25.0) 6 (13.0) 17 (37.0)
Type of heart failure
HF reduced ejection fraction 17 (18.5) 7 (15.2) 10 (21.7)
HF preserved ejection fraction 70 (76.1) 37 (80.4) 33 (71.7)
‘Isolated’ right-sided HF 5 (5.4) 2 (4.3) 3 (6.5)
Baseline scores on functional capacity and health status, mean (SD)
6MWT distance in meters 283.4 (72.1) 282.0 (79.5) 284.8 (70.4)
EQ-5D 0.67 (0.21) 0.67 (0.23) 0.68 (0.18)
PCS 41.2 (9.0) 42.7 (9.0) 39.8 (8.7)
MCS 50.8 (8.9) 50.5 (9.9) 51.1 (7.8)
MLHF 28.5 (6.8) 27.6 (6.7) 29.5 (7.6)
Values are numbers (percentage) unless stated otherwise.
IQR, interquartile range; MRC, Medical Research Council; BMI, body mass index; SD, standard deviation; NTproBNP, N-terminal pro B-type natriuretic peptide; ECG, electrocardiogram;
TIA, transient ischemic attack; COPD, chronic obstructive pulmonary disease; ACE-inhibitor, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineral-
ocorticoid receptor antagonist; 6MWT, six-minutewalk test; EQ-5D, EuroQol-5 Dimensions questionnaire; PCS, physical component summary;MCS,mental component summary;MLHF,
Minnesota Living with Heart Failure questionnaire.
a MRC score ≥ 3means that patients reportwalking slower than contemporaries on level ground because of breathlessness or need to stop for breathwhenwalking at his/her own pace,
or shortness of breath at even lower exercise.
b The conversion factor for NT-proBNP is 1 pg/ml = 0.118 pmol/l.
c The ECGwas considered abnormalwhen one of the followingwas present; atrialﬁbrillation, sinus or other tachycardia (heart rate N 100 beats/min), left and right bundle branch block
(complete and incomplete), left anterior and posterior block, left ventricular hypertrophy, pathological Q-waves suspected for previousmyocardial infarction, P-wave abnormalities com-
patible with left atrial enlargement, any ST and T-wave abnormalities, or second- or third-degree atrioventricular block.
d Comorbidities as mentioned by the patient with history taking.
e Previous myocardial infarction, angina pectoris, percutaneous coronary intervention or coronary artery bypass grafting.
179E.E.S. van Riet et al. / International Journal of Cardiology 217 (2016) 174–1824. Discussion
A single training of GPs in optimizing HF drug treatment did not re-
sult in increased HFmedication uptake in patients with newly detected
HFrEF and HFpEF. There was also no signiﬁcant effect on health status
between the intervention group and the care as usual group after six
months of follow-up. However, patients in the intervention group
showed an improvement in functional capacity as measured with the
6MWT (mean difference 28 m, 95% CI 3 to 53), more often visited the
GP (RR 1.8; 95% CI 1.3 to 2.5) and less often consulted a cardiologist
(RR 0.6; 95% CI 0.3 to 1.1).Our single half-day training of GP's did not clearly result in better HF
medication uptake in patients with newly detected HFrEF and HFpEF.
Some changes in prescription occurred, but these did not result in
clear differences between the intervention and care as usual group.
Numbers were too small to explore changes in dosage during the
follow-up. For HFpEF cases the lack of effect in drug uptake is quite un-
derstandable; it is difﬁcult to catch ﬁne-tuning of blood pressure and
subtle diuretic treatment adjustments during periods of ﬂuid overload.
For HFrEF we had hoped on higher prescribed percentages of the
three types of medication that are the mainstay of HFrEF therapy, i.e.
diuretics, ACE-inhibitors or ARBs, and beta-blockers.
Table 2
Changes in drug treatment during six months follow-up in the care as usual and intervention group, separately for those with HFrEF and HFpEF*
HFrEF HFpEF
Intervention
(n = 7)
Care as usual
(n = 10)
Intervention
(n = 36)
Care as usual
(n = 33)
Loop/thiazide diuretics
No use at begin and end 3 (42.9) 4 (40.0) 15 (41.7) 8 (24.2)
Continued use 1 (14.3) 4 (40.0) 13 (36.2) 19 (57.5)
Up-titrated 1 (14.3) 2 (20.0) 2 (5.6) 1 (3.0)
Initiated 2 (28.6) 0 6 (16.7) 5 (15.2)
Stopped 0 0 0 0
ACE-inhibitors/ARBs
No use at begin and end 2 (28.6) 3 (30.0) 10 (27.8) 6 (18.2)
Continued use 3 (42.9) 4 (40.0) 17 (47.2) 18 (54.5)
Up-titrated 2 (28.6) 1 (10.0) 3 (8.3) 5 (15.2)
Initiated 0 2 (20.0) 5 (13.9) 2 (6.1)
Stopped 0 0 1 (2.8) 2 (6.1)
B-blockers
No use at begin and end 1 (14.3) 5 (50.0) 23 (63.9) 14 (42.4)
Continued use 3 (42.9) 4 (40.0) 10 (27.8) 13 (39.4)
Up-titrated 0 0 0 1 (3.0)
Initiated 1 (14.3) 1 (10.0) 3 (8.3) 4 (12.1)
Stopped 2 (28.6) 0 0 1 (3.0)
MRAs
No use at begin and end 7 10 35 (97.2) 27 (81.8)
Continued use 0 0 0 3 (7.7)
Up-titrated 0 0 0 0
Initiated 0 0 0 3 (9.1)
Stopped 0 0 1 (2.8) 0
Values are numbers (percentage).
* For this analysis we considered it not opportune to add the ﬁve patients to those with HFpEF, because of differences in drug therapy.
HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; MRA,
mineralocorticoid receptor antagonist.
Table 3
Mean baseline and follow-up scores on functional capacity as measured in distance with the 6 min walk test and health status measured with the EQ-5D, SF-36, and MLHF in the
intervention and care as usual group with differences between groups at the end of follow-up, with and without correction for the baseline score.
Baseline After 6 months follow-up Difference (95% CI) between groups in outcome at 6 months
Interv
7 HFrEF
39 HFpEF^
CAU
10 HFrEF
36 HFpEF^
Interv
7 HFrEF
39 HFpEF^
CAU
10 HFrEF
36 HFpEF^
Without correction Corrected for baseline distance or score
6MWT 282.0 284.8 314.9 287.7 27.2# (−6.6 to 61.1) 28.0 (2.9 to 53.1)
HFrEF 313.6 319.6 411.0 357.9 52.4 (−29.3 to 134.1) 55.9 (−16.3 to 128.1)
HFpEF 276.4 275.1 297.7 268.3 29.4 (−2.3 to 61.0) 28.2 (8.8 to 47.5)
EQ-5D 0.67 0.68 0.67 0.67 −0.01 (−0.11 to 0.10) −0.003 (−0.10 to 0.11)
HFrEF 0.83 0.77 0.86 0.71 0.16 (−0.03 to 0.35) 0.12 (−0.03 to 0.26)
HFpEF 0.64 0.66 0.64 0.66 −0.03 (−0.14 to 0.08) −0.02 (−0.13 to 0.09)
SF-36*
PCS 42.7 39.8 41.2 37.9 3.2 (−1.9 to 8.4) 1.0 (−3.1 to 5.0)
MCS 50.5 51.1 48.3 48.9 −0.6 (−4.9 to 3.6) −0.3 (−4.5 to 3.9)
PF 48.5 41.5 47.5 40.2 7.3 (0.6 to 13.9) 2.0 (−3.9 to 8.0)
RP 48.5 50.2 56.1 44.0 12.3 (−0.4 to 25.0) 12.2 (−1.3 to 23.1)
BP 64.5 62.8 67.9 63.7 4.4 (−3.6 to 12.4) 3.2 (−2.9 to 9.4)
GH 49.9 47.1 50.7 47.0 3.7 (−1.3 to 8.8) 2.2 (−2.1 to 6.4)
VT 58.3 55.7 58.5 52.8 5.7 (−0.0 to 11.5) 4.4 (−0.4 to 9.2)
SF 73.9 68.1 71.1 68.4 2.7 (−6.2 to 11.7) 0.1 (−7.3 to 7.5)
RE 78.5 71.8 73.9 72.5 1.1 (−14.0 to 16.3) −1.5 (−17.4 to 14.5)
MH 72.1 76.3 75.8 73.1 2.7 (−3.1 to 8.6) 5.1 (0.0 to 10.2)
MLHF 27.6 29.5 23.7 25.5 −1.8 (−6.1 to 2.5) −0.5 (−5.3 to 4.3)
HFrEF 24.1 28.2 14.0 19.6 −5.8 (−15.2 to 3.6) −4.0 (−13.5 to 5.4)
HFpEF 28.3 29.8 25.5 27.1 −1.7 (−6.5 to 3.2) −0.6 (−6.1 to 4.9)
^ Patients with right-sided heart failure were categorized as HFpEF for this analysis.
# The difference in thewalking distance of all patientswith HF is less than in both subgroups (HFrEF andHFpEF) separately, becauseHFrEF andHFpEF patientswere not equally distributed
over the intervention and control group, and HFrEF patients walked on average farther than those with HFpEF or right-sided HF.
* SF-36 scores subdivided in those with HFrEF and HFpEF are not mentioned because differences in outcomes were marginal. Data are available on request.
95% CI, 95% conﬁdence interval; interv, intervention group; CAU, care as usual group; 6MWT, six-minutewalk test; HFrEF, heart failurewith reduced ejection fraction; HFpEF, heart failure
with preserved ejection fraction; EQ-5D, EuroQol-5 Dimensions questionnaire; SF-36 Short Form-36; PCS, physical component summary;MCS,mental component summary; PF, physical
functioning; RP, role limitation due to physical problems; BP, bodily pain; GH, general health; VT, vitality; DF, social functioning; RE, role limitation due to emotional problems;MH,mental
health; MLHF, Minnesota Living with Heart Failure questionnaire.
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Table 4
Health care use in the care as usual and intervention group during follow-up.
Intervention
(n = 46)
Care as usual
(n = 46)
RR
(95% CI)
6 months follow-up
Total number of HF-related patient
contacts with the GP
134 80 1.8 (1.3 to 2.5)
12 months follow-up
Total number of patient contacts
with the cardiologist
22 42 0.6 (0.3 to 1.1)
of which HF-related 6 13 0.5 (0.1 to 1.5)
RR, rate ratio; 95% CI, 95% conﬁdence interval; HF, heart failure; GP, general practitioner.
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inhibitors or ARBs (72% vs. 70%) and beta-blockers (57% vs. 50%) was
similar to care as usual, and the large majority already used these
drugs at baseline, most likely for hypertension. This high baseline up-
take of cardiovascular drugs also used in HF reduced the room for im-
provement. In previous studies that assessed prescription rates in
primary care patients with HF similar prescription rates were found
[7,8,31]. Prescription rates were higher in a study evaluating selectively
patients with HFrEF, not HFpEF, in primary care; 80% were on ACE-
inhibitors or ARBs, and 75% on beta-blockers. Also diuretics (60% vs.
on average 84%) and MRAs (0% vs. on average 26%) were more often
used in this study than in ours [32].
When interpreting our results, one has to realize that we evaluated
newly screen-detected cases. The limited severity of symptoms in these
early stages of HF may have hampered the motivation of both patient
and GP to initiate or further up-titrate cardiovascular drugs. In our
study, only one participant was hospitalized during the twelve months
follow-up period and 13% visited the cardiology outpatient clinic for HF.
These low numbers indicate that patients were detected very early in
their disease trajectory.
Another possible explanation for the lack of improvement in pre-
scription rates is the short duration of our training. We cannot tell
whether our training increased knowledge and conﬁdence of the GP
while not affecting their actual evidence-based drug prescription. We
did not assess the GPs' reasons for non-prescription. Also in other re-
search ﬁelds, such as diabetes and asthma, educational interventions
aimed at GPs often failed to improve prescription rates [33,34]. System-
atic reviews have noted that passive disseminating approaches are gen-
erally ineffective and unlikely to result in behavior change. Multifaceted
interventions targeting different barriers to change and reminders are
more likely to be effective than single interventions [35,36].
Interestingly, we did ﬁnd an improvement in functional capacity
as measured by the 6MWT. While this ﬁnding could be the result of
chance, we think the effect is likely true, especially for patients
with HFpEF. Even after additional adjustment for baseline covariates
(which in theory should not be necessary after randomization), the
impact on walking distance remained signiﬁcant in patients with
HFpEF. Due to the small number of HFrEF patients, we cannot make
deﬁnitive conclusions regarding results for these patients. The func-
tional capacity of participants in our study was comparable to previ-
ous studies performed in patients with HF, with average 6MWT
distance ranging from 125 to 499 m [37]. Mean distance in our
study was 292 m, indicating a moderate functionality, known to be
associated with increased mortality [16]. To our knowledge, we are
the ﬁrst to study the effect of training GPs in HFpEF management. It
could well be that extra attention (reﬂected in the higher number
of GP visits in the intervention group) for blood pressure control,
ﬂuid retention, adequate treatment of comorbidities and monitoring
the disease trajectory in these patients results in optimization of
functionality and increase in the walking distance. Since the number
of included patients in our studywas low, a larger trial should be per-
formed to conﬁrm our ﬁndings.Such a future trial could be extended with a third arm, in which
HFpEF patients receive the same drug treatment as HFrEF patients. It
has been argued that standard medication therapy for HFrEF is likely
to be beneﬁcial also for HFpEF, despite the lack of a signiﬁcant result
onmortality [38,39]. This lack of effect is thought to be caused by exclu-
sion, or inclusion of only the ‘purest’ forms, of HFpEF in the landmark
clinical trials. A primary care trial would be ideally suited to establish
or rule out an effect, since ‘true’ HFpEF patients (female, older, with co-
morbidities) are predominantly treated by their general practitioner
and not in the hospital setting. Recent population-based opportunistic
screening studies showed that up to even 80% of HF cases in the com-
munity are HFpEF, and only 20% HFrEF [40–42], hence recruitment
should not be a problem.
The major strength of our study is thereby the pragmatic approach
showing the results achievable in everyday general practice. Other
strengths include the randomized design and the blinding of partici-
pants to the treatment assignment.
Some limitations of our study need to be addressed. Firstly, although
we were able to recruit 30 GPs in our study, we included a somewhat
lower number of patients (92) than the targeted 104 participants re-
quired to show an effect on the 6MWT. In the power calculation, we
used a rather high value for the ICC (0.05), however, while previous
studies indicated that ICCs of health outcomes are generally lower
than 0.05 [43]. As it turned out, our study has enough power to show
a difference in walking distance between the intervention arms, but
the 95% conﬁdence limits for subgroups of HF patients (and especially
for HFrEF) were wide.
Secondly, functional capacity was not one of the original outcomes
of our study. Uptake of HF medication was used for power calculations.
However, a few months after the start of the study it became clear that
wehad anunexpected high prevalence of HFpEF among theparticipants
with newly diagnosed HF (around 75% of all HF). Current medication
does not clearly alter prognosis in these patients. We therefore decided
to add functional capacity as a patient relevant outcome, and based our
new power calculation on this outcome. These changes were done
before any data analysis, and were approved by the Medical Ethics
committee.
Thirdly, due to the delayed introduction of the 6MWT, one third of
the patients (33%) missed the opportunity to take this test at baseline.
At follow-up we had 29% missings on the 6MWT outcome. Almost half
of those who did not participate declined because they did not feel
physically well enough. The majority of the others just ‘did not feel
like it’. However, by state-of-the-art imputation techniques we could
provide adequate predictions of the outcome.
Better results of a GP training programmay be possible with a more
intensiﬁed strategy, such as by addition of a clinical decision support
system embedded within the electronic medical ﬁles, a medication
feedback system, educational bulletins, or computer-based reminder
systems. Adequate tackling barriers can also help to overcomeorganiza-
tional difﬁculties in primary care.
5. Conclusion
A single training session forGPs designed to improve outcomes for pa-
tients ≥65 years with newly detected HF did not result in an increase in
HF medication uptake and health status, but improved walking distance.
Registration and funding
This trial is registered at ClinicalTrials.gov (NCT01202006), and was
supported by a research grant from the Dutch Heart Foundation
(2009B048).
Conﬂicts of interest
All authors declare no conﬂicting interests.
182 E.E.S. van Riet et al. / International Journal of Cardiology 217 (2016) 174–182Acknowledgements
We thank all participating GPs, the personnel of the outpatient clinic
of the Julius center (Utrecht, The Netherlands), and the personnel of
nursing home Bovenwegen (Zeist, The Netherlands).
This study was supported by a research grant from the Dutch Heart
Foundation (2009B048).
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijcard.2016.04.171.
References
[1] A. Mosterd, A.W. Hoes, M.C. De Bruyne, J.W. Deckers, A. Hofman, D.E. Grobbee, Prev-
alence of heart failure and left ventricular dysfunction in the general population;
The Rotterdam Study, Eur. Heart J. 20 (6) (1999) 447–455.
[2] T. Hoekstra, I. Lesman-Leegte, D.J. van Veldhuisen, R. Sanderman, T. Jaarsma, Quality
of life is impaired similarly in heart failure patients with preserved and reduced
ejection fraction, Eur. J. Heart Fail. 13 (9) (2011) 1013–1018.
[3] F.D. Hobbs, J.E. Kenkre, A.K. Roalfe, R.C. Davis, R. Hare, M.K. Davies, Impact of heart
failure and left ventricular systolic dysfunction on quality of life: a cross-sectional
study comparing common chronic cardiac and medical disorders and a representa-
tive adult population, Eur. Heart J. 23 (23) (2002) 1867–1876 (Xxxx).
[4] J.J. McMurray, S. Adamopoulos, S.D. Anker, et al., ESC guidelines for the diagnosis
and treatment of acute and chronic heart failure 2012: The Task Force for the Diag-
nosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Soci-
ety of Cardiology. Developed in collaboration with the Heart Failure Association
(HFA) of the ESC, Eur. J. Heart Fail. 14 (8) (2012) 803–869.
[5] A. Mosterd, A.W. Hoes, Clinical epidemiology of heart failure, Heart 93 (9) (2007)
1137–1146.
[6] W.J. Remme, J.J. McMurray, F.D. Hobbs, et al., Awareness and perception of heart
failure among European cardiologists, internists, geriatricians, and primary care
physicians, Eur. Heart J. 29 (14) (2008) 1739–1752.
[7] F.J. Bongers, F.G. Schellevis, C. Bakx, W.J. van den Bosch, J. van der Zee, Treatment of
heart failure in Dutch general practice, BMC Fam. Pract. 5 (7) (2006) 40.
[8] M. Bosch, M. Wensing, J.C. Bakx, T. van der Weijden, A.W. Hoes, R.P. Grol, Current
treatment of chronic heart failure in primary care; still room for improvement, J.
Eval. Clin. Pract. 16 (3) (2010) 644–650.
[9] W.N. Kasje, P. Denig, P.A. de Graeff, F.M. Haaijer-Ruskamp, Perceived barriers for
treatment of chronic heart failure in general practice; are they affecting perfor-
mance? BMC Fam. Pract. 6 (1) (2005) 19.
[10] A. Fuat, A.P. Hungin, J.J. Murphy, Barriers to accurate diagnosis and effective man-
agement of heart failure in primary care: qualitative study, BMJ 326 (7382)
(2003) 196.
[11] J. Fürthauer, M. Flamm, A. Sönnichsen, Patient and physician related factors of ad-
herence to evidence based guidelines in diabetesmellitus type 2, cardiovascular dis-
ease and prevention: a cross sectional study, BMC Fam. Pract. 14 (2013) 47.
[12] E.E. Van Riet, A.W. Hoes, A. Limburg, H. van der Hoeven, M.A. Landman, F.H. Rutten,
Strategy to recognize and initiate treatment of chronic heart failure in primary care
(STRETCH): a cluster randomized trial, BMC Cardiovasc. Disord. 14 (2014) 1.
[13] A.W. Hoes, A.A. Voors, F.H. Rutten, J. Van Lieshout, P.G. Janssen, E.P. Walma, NHG-
Standaard Hartfalen, Huisarts Wet, 53(7) 2010, pp. 368–389.
[14] ATS Committee on Proﬁciency Standards for Clinical Pulmonary Function
Laboratories, ATS statement: guidelines for the six-minute walk test, Am. J. Respir.
Crit. Care Med. 166 (1) (2002) 111–117.
[15] B. Pollentier, S.L. Irons, C.M. Benedetto, et al., Examination of the six minute walk
test to determine functional capacity in people with chronic heart failure: a system-
atic review, Cardiopulm. Phys. Ther. J. 21 (1) (2010 Mar) 13–21.
[16] T. Rasekaba, A.L. Lee, M.T. Naughton, T.J. Williams, A.E. Holland, The six-minute walk
test: a useful metric for the cardiopulmonary patient, Intern. Med. J. 39 (8) (2009)
495–501.
[17] J. Spertus, E. Peterson, M.W. Conard, et al., Monitoring clinical changes in patients
with heart failure: a comparison of methods, Am. Heart J. 150 (4) (2005) 707–715.
[18] N.K. Aaronson, M. Muller, P.D. Cohen, et al., Translation, validation, and norming of
the Dutch language version of the SF-36 Health Survey in community and chronic
disease populations, J. Clin. Epidemiol. 51 (11) (1998) 1055–1068.[19] C.A. McHorney, J.E. Ware Jr., A.E. Raczek, The MOS 36-Item Short-Form Health Sur-
vey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and
mental health constructs, Med. Care 31 (3) (1993) 247–263.
[20] EuroQol Group, EuroQol—a new facility for themeasurement of health-related qual-
ity of life, Health Policy 16 (3) (1990) 199–208.
[21] R. Brooks, EuroQol: the current state of play, Health Policy 37 (1) (1996) 53–72.
[22] O. Garin, M. Ferrer, A. Pont, et al., Disease-speciﬁc health-related quality of life ques-
tionnaires for heart failure: a systematic review with meta-analyses, Qual. Life Res.
18 (1) (Feb 2009) 71–85.
[23] S.J. Walters, J.E. Brazier, Comparison of the minimally important difference for two
health state utility measures: EQ-5D and SF-6D, Qual. Life Res. 14 (6) (2005)
1523–1532.
[24] K.W. Wyrwich, J.A. Spertus, K. Kroenke, W.M. Tierney, A.N. Babu, F.D. Wolinsky,
Clinically important differences in health status for patients with heart disease: an
expert consensus panel report, Am. Heart J. 147 (4) (2004) 615–622.
[25] L.G. Olsson, K. Swedberg, A.L. Clark, K.K.Witte, J.G. Cleland, Six minute corridor walk
test as an outcomemeasure for the assessment of treatment in randomized, blinded
intervention trials of chronic heart failure: a systematic review, Eur. Heart J. 26 (8)
(2005) 778–793.
[26] H. Lamberts, S.K. Oskam, I.M. Okkes, The clinical relationship between symptoms
and the ﬁnal diagnosis in general practice, determined by means of posterior prob-
abilities calculated on the basis of the Transition Project, Ned. Tijdschr. Geneeskd.
149 (46) (2005) 2566–2572.
[27] M.J. Campbell, Cluster randomized trials in general (family) practice research, Stat.
Methods Med. Res. 9 (2) (2000) 81–94.
[28] A. Donner, N. Birkett, C. Buck, Randomization by cluster. Sample size requirements
and analysis, Am. J. Epidemiol. 114 (6) (1981) 906–914.
[29] A.R. Donders, G.J. van der Heijden, T. Stijnen, K.G. Moons, Review: a gentle introduc-
tion to imputation of missing values, J. Clin. Epidemiol. 59 (10) (2006) 1087–1091.
[30] R.H. Groenwold, A.R. Donders, K.C. Roes, F.E. Harrell Jr., K.G. Moons, Dealing with
missing outcome data in randomized trials and observational studies, Am. J.
Epidemiol. 175 (3) (2012) 210–217.
[31] M. Cancian, A. Battaggia, M. Celebrano, et al., The care for chronic heart failure by
general practitioners. Results from a clinical audit in Italy, Eur. J. Gen. Pract. 19 (1)
(2013) 3–10.
[32] F. Peters-Klimm, T. Müller-Tasch, D. Schellberg, et al., Guideline adherence for phar-
macotherapy of chronic systolic heart failure in general practice: a closer look on
evidence-based therapy, Clin. Res. Cardiol. 97 (4) (2008) 244–252.
[33] N.D. Sulaiman, C.A. Barton, S.T. Liaw, et al., Do small group workshops and locally
adapted guidelines improve asthma patients' health outcomes? A cluster random-
ized controlled trial, Fam. Pract. 27 (3) (2010) 246–254.
[34] A.T. Reutens, R. Hutchinson, T. Van Binh, et al., The GIANT study, a cluster-
randomised controlled trial of efﬁcacy of education of doctors about type 2 diabetes
mellitus management guidelines in primary care practice, Diabetes Res. Clin. Pract.
98 (1) (2012) 38–45.
[35] J.M. Grimshaw, L. Shirran, R. Thomas, et al., Changing provider behavior: an over-
view of systematic reviews of interventions, Med. Care 39 (8 Suppl. 2) (2001)
II2–I45.
[36] A.D. Oxman, M.A. Thomson, D.A. Davis, R.B. Haynes, No magic bullets: a systematic
review of 102 trials of interventions to improve professional practice, CMAJ 153
(10) (1995) 1423–1431.
[37] Rector TS. Overview of TheMinnesota Livingwith Heart Failure Questionnaire. 1–1-05.
[38] A. Coats, L. Shewan, The Management of Heart Failure with Preserved Ejection Frac-
tion (HFpEF), Int. Cardiovasc. Forum J. 1 (2014) 108–112.
[39] J. Sanderson, Comments on “The management of Heart Failure with preserved ejec-
tion fraction”, Int. Cardiovasc. Forum J. 1 (2014) 166.
[40] E.E. Van Riet, A.W. Hoes, A. Limburg, M.A. Landman, H. van der Hoeven, F.H. Rutten,
Prevalence of unrecognized heart failure in older persons with shortness of breath
on exertion, Eur. J. Heart Fail. 16 (7) (2014) 772–777.
[41] L.J. Boonman-de Winter, F.H. Rutten, M.J. Cramer, M.J. Landman, A.H. Liem, G.E.
Rutten, A.W. Hoes, High prevalence of previously unknown heart failure and left
ventricular dysfunction in patients with type 2 diabetes, Diabetologia 55 (8)
(2012) 2154–2162.
[42] Y. Van Mourik, L.C. Bertens, M.J. Cramer, J.W. Lammers, J.B. Reitsma, K.G. Moons,
A.W. Hoes, F.H. Rutten, Unrecognized heart failure and chronic obstructive pulmo-
nary disease in frail elderly through a near-home targeted screening strategy, J.
Am. Board Fam. Med. 27 (6) (2014) 811–821.
[43] M.K. Campbell, J. Mollison, N. Steen, J.M. Grimshaw, M. Eccles, Analysis of cluster
randomized trials in primary care: a practical approach, Fam. Pract. 17 (2) (2000)
192–196.
